

Meeting abstract

Open Access

Survival among AIDS patients with and without non-Hodgkin's lymphoma, and NHL-HIV-negative patients

Patricia Cornejo-Juárez*¹, Patricia Volkow-Fernández¹, Alejandro Avilés-Salas² and Ernesto Calderón-Flores³

Address: ¹Department of Infectious Diseases. Instituto Nacional de Cancerología, Mexico City, Mexico, ²Department of Pathology. Instituto Nacional de Cancerología, Mexico City, Mexico and ³Department of Hematology-Oncology. Instituto Nacional de Cancerología, Mexico City, Mexico

Email: Patricia Cornejo-Juárez* - patcornejo@yahoo.com

* Corresponding author

from 24th Annual Meeting of the National Cancer Institute of Mexico
Mexico City, Mexico. 14–17 February 2007

Published: 5 February 2007

BMC Cancer 2007, 7(Suppl 1):A40 doi:10.1186/1471-2407-7-S1-A40

This article is available from: <http://www.biomedcentral.com/1471-2407/7/S1/A40>

© 2007 Cornejo-Juárez et al; licensee BioMed Central Ltd.

Background

The risk of non Hodgkin's lymphoma (NHL) is 150–250 times higher among HIV infected patients. In developed countries with open access to highly active antiretroviral therapy (HAART), the prognosis of these patients appears to be impacted positively, and survival in some groups can be similar to non-HIV infected patients. Recent data has shown improved survival among NHL-HIV+ patients receiving standard chemotherapy (QT) HAART, with acceptable range of toxicity.

Objective

To analyze the median survival of patients with AIDS with and without NHL and NHL-HIV negative patients.

Materials and methods

We retrospectively reviewed all medical records of patients with NHL-HIV+ seen from January 1990 to December 2005 at the Instituto Nacional de Cancerología in Mexico City, Mexico. We used as control groups patients with AIDS (defining-event non-lymphoma related), and patients with NHL treated as well at our institution, diagnosis made \pm 3 years, with same gender and age \pm 5 years. We recorded clinical, laboratory and pathology data; survival or follow-up time was calculated from date of diagnosis to death or to the date when the patient was last seen.

Results

Sixty-nine patients were diagnosed with NHL-HIV. AIDS control patients (n = 93) were divided into no-HAART and HAART; and NHL/HIV negative control patients (n = 90) were divided into incomplete (<3 cycles or <100% of total dose), and complete chemotherapy (Table 1)

Conclusion

Survival in patients with AIDS is better than in NHL/HIV+ and NHL/HIV-. The use of HAART has significantly improved the prognosis. Mean survival with the use of a complete chemotherapy regime is similar in patients with NHL and in patients with NHL/HIV+.

Table 1: Mean survival for NHL/HIV+, NHL/HIV negative and AIDS groups

	NHL/HIV+ (n = 69)	AIDS (n = 93)	p
No-HAART (months ± SD)	5.01 ± 7.7 (n = 27)	25.9 ± 25.12 (n = 40)	0.001
HAART (months ± SD)	15.75 ± 19.4 (n = 42)	50 ± 37.9 (n = 53)	<0.0001
Total (months ± SD)	11.5 ± 16.7	39.7 ± 35	<0.0001
	NHL/HIV	NHL (n = 90)	
Incomplete chemotherapy (months ± SD)	4.32 ± 5.5 (n = 40)	1.84 ± 1.66 (n = 22)	0.04
Complete chemotherapy(months ± SD)	21.3 ± 20.26 (n = 29)	29.07 ± 36.27 (n = 68)	0.286
Total(months ± SD)	11.5 ± 16.7	22.41 ± 33.61	0.01

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

